Table 2.

Summary of mortality or first hospitalization events from first dose of study drug while on-treatment^*

Event	Placebo	Revusiran	Hazard ratio (95% CI)
	(n = 66)	(n = 140)	(revusiran versus placebo)†
	n (%)	n (%)
All-cause mortality	2 (3.0)	18 (12.9)	5.3 (1.2, 22.8)
CV mortality‡	2 (3.0)	16 (11.4)	4.6 (1.0, 19.9)
All-cause hospitalization§	24 (36.4)	67 (47.9)	1.4 (0.9, 2.2)
CV hospitalization	21 (31.8)	49 (35.0)	1.1 (0.7, 1.8)
HF hospitalization	13 (19.7)	41 (29.3)	1.6 (0.8, 2.9)

^*On-treatment events classified as all events that occurred on or prior to November 4, 2016.^†The hazard ratio with associated 95% CI is based on the Cox proportional hazard models for time to events with randomized treatment arm as a covariate.^‡Deaths observed were adjudicated as heart failure or sudden cardiac death and did not include any vascular events (e.g., stroke, AMI, or CV hemorrhage). ^§All-cause hospitalization events occurring on-treatment include any all-cause hospitalization events (CV and non-CV)

AMI acute myocardial infarction, CI confidence interval, CV cardiovascular, HF heart failure